PAREXEL International appoints Simon Harford as Senior Vice President and Chief Financial Officer
Appointment Effective June 1, 2017
(firmenpresse) - LONDON, February 28, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the appointment of Simon Harford as Senior Vice President and Chief Financial Officer effective June 1, 2017. He will serve on PAREXEL''s Business Review Committee, the Company''s senior-most leadership team, and assist in developing and implementing PAREXEL''s strategic objectives. Mr. Harford will be based at the Company’s corporate headquarters in Waltham, Massachusetts.
“Simon brings to PAREXEL more than three decades of global financial management and investor relations experience in the pharmaceutical industry. During his career, he has successfully managed large global finance functions, implemented transformational projects, and improved operational effectiveness,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL. “Simon’s leadership will strengthen our ability to accelerate growth and improve profitability as we implement our corporate strategy.”
Mr. Harford joins PAREXEL from GlaxoSmithKline plc (GSK), where he most recently served as Senior Vice President, Finance, for the company’s Global Pharmaceuticals business based at GSK’s global headquarters in Brentford, England. Prior to joining GSK, Mr. Harford served as Group Vice President and Controller for Avon Products, Inc., in New York. Additionally, he spent two decades with Eli Lilly and Company in various finance leadership roles across Europe and in Indianapolis, most notably as Head of Investor Relations and as Vice President and Controller.
“PAREXEL has a long and distinguished history of providing innovative services to the biopharmaceutical industry, a record that has positioned the Company for long-term growth,” said Mr. Harford. “I look forward to working with PAREXEL’s management team as we leverage growth opportunities and deliver value to our shareholders.”
Mr. Harford, a native of the United Kingdom, holds an MBA from the University of Virginia’s Darden Graduate School of Business.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialisation continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 85 locations in 51 countries around the world, and had approximately 19,625 employees in the second quarter. For more information about PAREXEL International visit www.PAREXEL.com.
Erik Kopp
Tel.: +1 781-434-5304
Email: erik.kopp(at)PAREXEL.com
Jenny Radloff, PAN Communications
Tel: +1 617-502-4300
Email: PAREXEL(at)pancomm.com
Datum: 02.03.2017 - 07:49 Uhr
Sprache: Deutsch
News-ID 1490135
Anzahl Zeichen: 2164
contact information:
Contact person: Fran Cator
Town:
Lincoln
Phone: 01522 883640
Kategorie:
Pharmaceuticals & Biotech
Typ of Press Release: bitte
type of sending: Veröffentlichung
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 523 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PAREXEL International appoints Simon Harford as Senior Vice President and Chief Financial Officer
"
steht unter der journalistisch-redaktionellen Verantwortung von
RealWire (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
